Mold-Tek Packaging Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
MOLDTKPAC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 3.1 pts less than its Packaging peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mold-Tek Packaging reported FY25 revenue of Rs 781.32 crore, up 11.83% from Rs 698.65 crore last year, driven by 7.30% growth in sales volume to 38,264 MT. EBITDA rose 6.98% to Rs 143.83 crore, but PAT declined 9.05% to Rs 60.55 crore due to sharply higher finance costs (up ~89% to Rs 13.90 crore) and depreciation (up ~26% to Rs 48.69 crore). For Q4, revenue grew 14.55% to Rs 202.61 crore and EBITDA rose 9.21% to Rs 39.08 crore, while net profit fell 9.47% to Rs 16.23 crore. The newly-launched Pharma-Pack division crossed break-even in Q4 with sales tripling sequentially, and capacity expansion is ongoing across paints, IML printing, and pharma segments.
Mixed signals for shareholders — top-line growth is healthy and the pharma break-even is a positive long-term trigger, but bottom-line pressure from rising finance and depreciation costs and a 37% jump in borrowings (to Rs 181 crore) may weigh on near-term sentiment. The auditor issued an unmodified (clean) opinion, and an interim dividend of Rs 2 per share was already paid during the year.